69 related articles for article (PubMed ID: 10387996)
1. The Clinical Development of Paclitaxel: A Successful Collaboration of Academia, Industry and the National Cancer Institute.
Donehower RC
Oncologist; 1996; 1(4):240-243. PubMed ID: 10387996
[TBL] [Abstract][Full Text] [Related]
2. The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute.
Donehower RC
Stem Cells; 1996 Jan; 14(1):25-8. PubMed ID: 8820947
[TBL] [Abstract][Full Text] [Related]
3. Closing Remarks.
Reed E
Oncologist; 1996; 1(4):276-277. PubMed ID: 10388002
[TBL] [Abstract][Full Text] [Related]
4. The NCI All Ireland Cancer Conference.
Johnston PG; Daly PA; Liu E
Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Better infrastructure: industry-academia partnerships--a marriage of convenience?
Abraham E
Crit Care Med; 2009 Jan; 37(1 Suppl):S159-64. PubMed ID: 19104217
[TBL] [Abstract][Full Text] [Related]
7. Taxol commercial supply strategy.
DeFuria MD; Horovitz Z
J Natl Cancer Inst Monogr; 1993; (15):195-8. PubMed ID: 7912526
[TBL] [Abstract][Full Text] [Related]
8. Research on cancer diagnosis in Malaysia: current status.
Looi LM; Zubaidah Z; Cheah PL; Cheong SK; Gudum HR; Iekhsan O; Ikram SI; Jamal R; Mak JW; Othman NH; Puteri JN; Rosline H; Sabariah AR; Seow HF; Sharifah NA;
Malays J Pathol; 2004 Jun; 26(1):13-27. PubMed ID: 16190103
[TBL] [Abstract][Full Text] [Related]
9. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
10. In Response To: Professor Cassileth's manuscript on "Alternative and Complementary Cancer Treatments," Featured in The Oncologist 1996;1:173-179.
Quah TC
Oncologist; 1996; 1(5):324-325. PubMed ID: 10388010
[TBL] [Abstract][Full Text] [Related]
11. BMS-247550 Bristol-Myers Squibb/GBF.
Lin N; Brakora K; Seiden M
Curr Opin Investig Drugs; 2003 Jun; 4(6):746-56. PubMed ID: 12901236
[TBL] [Abstract][Full Text] [Related]
12. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
13. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
14. Surgeons: A Future Role in Clinical Trials?
Rusch VW
Oncologist; 1997; 2(3):V-VI. PubMed ID: 10388050
[TBL] [Abstract][Full Text] [Related]
15. Beware the Medical-Industrial Complex.
Stevens CW; Glatstein E
Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
[TBL] [Abstract][Full Text] [Related]
16. New science-based endpoints to accelerate oncology drug development.
Kelloff GJ; Sigman CC
Eur J Cancer; 2005 Mar; 41(4):491-501. PubMed ID: 15737552
[TBL] [Abstract][Full Text] [Related]
17. Outcomes research collaborations between third-party payers, academia, and pharmaceutical manufacturers: What can we learn from clinical research?
Eichler HG; Kong SX; Grégoire JP
Eur J Health Econ; 2006 Jun; 7(2):129-35. PubMed ID: 16485122
[TBL] [Abstract][Full Text] [Related]
18. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy.
Lee FY; Borzilleri R; Fairchild CR; Kim SH; Long BH; Reventos-Suarez C; Vite GD; Rose WC; Kramer RA
Clin Cancer Res; 2001 May; 7(5):1429-37. PubMed ID: 11350914
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel in Breast Cancer.
Perez EA
Oncologist; 1998; 3(6):373-389. PubMed ID: 10388129
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
